EGFR and non-small cell lung carcinoma: Given the high efficacy and mild side effects of the two RET-specific inhibitors, it is worth investigating their clinical utility to treat EGFR-mutated NSCLC patients who acquired RET oncogenic alterations after TKI resistance, especially those receiving 3rd-G EGFR-TKIs.